JP2024503698A5 - - Google Patents

Info

Publication number
JP2024503698A5
JP2024503698A5 JP2023543034A JP2023543034A JP2024503698A5 JP 2024503698 A5 JP2024503698 A5 JP 2024503698A5 JP 2023543034 A JP2023543034 A JP 2023543034A JP 2023543034 A JP2023543034 A JP 2023543034A JP 2024503698 A5 JP2024503698 A5 JP 2024503698A5
Authority
JP
Japan
Prior art keywords
rbm
fusion protein
vaccine according
cov
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023543034A
Other languages
English (en)
Japanese (ja)
Other versions
JP7879130B2 (ja
JP2024503698A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/012607 external-priority patent/WO2022155524A1/en
Publication of JP2024503698A publication Critical patent/JP2024503698A/ja
Publication of JP2024503698A5 publication Critical patent/JP2024503698A5/ja
Application granted granted Critical
Publication of JP7879130B2 publication Critical patent/JP7879130B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023543034A 2021-01-15 2022-01-14 変異型株ベースのコロナウイルスワクチン Active JP7879130B2 (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202163138228P 2021-01-15 2021-01-15
US63/138,228 2021-01-15
US202163140921P 2021-01-24 2021-01-24
US63/140,921 2021-01-24
US202163161439P 2021-03-15 2021-03-15
US63/161,439 2021-03-15
US202163173972P 2021-04-12 2021-04-12
US63/173,972 2021-04-12
US202163193558P 2021-05-26 2021-05-26
US63/193,558 2021-05-26
US202163222930P 2021-07-16 2021-07-16
US63/222,930 2021-07-16
US202163241944P 2021-09-08 2021-09-08
US63/241,944 2021-09-08
US202163283795P 2021-11-29 2021-11-29
US63/283,795 2021-11-29
US202163284565P 2021-11-30 2021-11-30
US63/284,565 2021-11-30
PCT/US2022/012607 WO2022155524A1 (en) 2021-01-15 2022-01-14 Variant strain-based coronavirus vaccines

Publications (3)

Publication Number Publication Date
JP2024503698A JP2024503698A (ja) 2024-01-26
JP2024503698A5 true JP2024503698A5 (cg-RX-API-DMAC10.html) 2025-04-14
JP7879130B2 JP7879130B2 (ja) 2026-06-23

Family

ID=80222159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023543034A Active JP7879130B2 (ja) 2021-01-15 2022-01-14 変異型株ベースのコロナウイルスワクチン

Country Status (6)

Country Link
US (1) US20240100151A1 (cg-RX-API-DMAC10.html)
EP (1) EP4277655A1 (cg-RX-API-DMAC10.html)
JP (1) JP7879130B2 (cg-RX-API-DMAC10.html)
AU (1) AU2022208057A1 (cg-RX-API-DMAC10.html)
CA (1) CA3208486A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022155524A1 (cg-RX-API-DMAC10.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
MX2021010075A (es) 2019-02-20 2021-12-10 Modernatx Inc Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
KR20230011369A (ko) * 2020-05-18 2023-01-20 칸시노 (상하이) 바이오테크놀로지스 컴퍼니 리미티드 mRNA 또는 mRNA 조성물, 및 이의 제조 방법 및 이의 용도
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
EP4366768A4 (en) * 2021-07-09 2025-05-21 ModernaTX, Inc. Pan-human coronavirus vaccines
US12397051B2 (en) * 2021-09-14 2025-08-26 Globe Biotech Limited Vaccine for use against coronavirus and variants thereof
AU2022358982A1 (en) * 2021-10-06 2024-05-23 Diosynvax Ltd Coronavirus vaccines
WO2023092069A1 (en) * 2021-11-18 2023-05-25 Modernatx, Inc. Sars-cov-2 mrna domain vaccines and methods of use
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
JP2025529906A (ja) * 2022-08-22 2025-09-09 ザ ヘンリー エム ジャクソン ファンデイション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド コロナウイルスに対するワクチン
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
WO2025166202A1 (en) 2024-01-31 2025-08-07 Modernatx, Inc. Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof
WO2026055709A1 (en) * 2024-09-09 2026-03-12 Washington University Mitochondria-facilitated delivery of mrna

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
WO2006009011A1 (ja) * 2004-07-15 2006-01-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute コロナウイルススパイクs1融合蛋白及びその発現ベクター
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
JP2010531640A (ja) 2007-06-29 2010-09-30 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 毒性化合物の分解方法
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
SG10201408164XA (en) 2007-12-11 2015-01-29 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
EA201492055A1 (ru) 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
ES2967701T3 (es) 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
SG10201801428RA (en) 2013-08-21 2018-03-28 Curevac Ag Method for increasing expression of rna-encoded proteins
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
HRP20220070T1 (hr) * 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
MA46023A (fr) * 2015-10-22 2019-07-03 Modernatx Inc Vaccin contre le virus de la grippe à large spectre
DE20164728T1 (de) * 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
WO2021154763A1 (en) * 2020-01-28 2021-08-05 Modernatx, Inc. Coronavirus rna vaccines
DE202021004130U1 (de) * 2020-02-04 2022-10-26 Curevac Ag Coronavirus-Vakzine
BR112022015565A2 (pt) * 2020-02-07 2022-09-27 Modernatx Inc Vacinas de domínio de mrna para sars-cov-2
EP4139616A1 (en) * 2020-04-22 2023-03-01 Pfizer Inc. Coronavirus vaccine
AU2021269042A1 (en) * 2020-05-07 2023-02-02 Translate Bio, Inc. Optimized nucleotide sequences encoding SARS-CoV-2 antigens

Similar Documents

Publication Publication Date Title
JP2024503699A5 (cg-RX-API-DMAC10.html)
JP2023513073A5 (cg-RX-API-DMAC10.html)
JP2024513999A5 (cg-RX-API-DMAC10.html)
JP2024514182A5 (cg-RX-API-DMAC10.html)
JP2024542188A5 (cg-RX-API-DMAC10.html)
ES3058501T3 (en) Rsv f protein mutants
ES2869199T3 (es) Sistemas de expresión
JP2022136230A5 (cg-RX-API-DMAC10.html)
IL278418B2 (en) Vaccine composition
TW202140518A (zh) 冠狀病毒疫苗
JP2024156964A5 (cg-RX-API-DMAC10.html)
JP2023546369A5 (cg-RX-API-DMAC10.html)
TW201202262A (en) Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
Ibañez et al. M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A
JP2022533318A (ja) 気道感染の治療または予防のためのサブユニットワクチン
BR112012024872B1 (pt) Composições farmacêuticas compreendendo um polipeptídeo contendo pelo menos um motivo cxxc e antígenos heterólogos e seus usos
JP2017538672A (ja) Cmv由来改変ウイルス様粒子
JP2013523887A5 (cg-RX-API-DMAC10.html)
JP2024542635A5 (cg-RX-API-DMAC10.html)
JP2019088329A5 (cg-RX-API-DMAC10.html)
JP2024539512A5 (cg-RX-API-DMAC10.html)
JP2010536878A (ja) インフルエンザタンパク質を製造および使用する組成物および方法
JP2021511077A (ja) インフルエンザウイルスワクチン及びその使用
JP2020519663A (ja) Rsv感染に対する防御免疫を誘導するための方法及び組成物
JP2023532290A5 (cg-RX-API-DMAC10.html)